Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Floor J Backes

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Gynecologic Oncology|January 29, 2023
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient populationPaulina J Haight, David A Barrington, Stephen M Graves, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Gynecologic Oncology Reports|July 7, 2023
Assessment of the feasibility of same-day discharge following minimally invasive hysterectomy in the elderly populationPaulina J Haight, Rachael N Piver, David A Barrington, et al.
Cancer|December 8, 2016
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group studyAbigail D Winder, Kruti P Maniar, Jian-Jun Wei, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Gynecologic Oncology|January 29, 2023
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient populationPaulina J Haight, David A Barrington, Stephen M Graves, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Gynecologic Oncology Reports|July 7, 2023
Assessment of the feasibility of same-day discharge following minimally invasive hysterectomy in the elderly populationPaulina J Haight, Rachael N Piver, David A Barrington, et al.
Cancer|December 8, 2016
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group studyAbigail D Winder, Kruti P Maniar, Jian-Jun Wei, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Pageof 12